Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 4068-4071

  De Jong, Floris A ^a   Mathijssen, Ron H J ^a   Xie, Rujia ^b   Verweij, Jaap ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DRUG METABOLITE; IRINOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY SURFACE; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG GLUCURONIDATION; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BODY SURFACE AREA; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCURONATES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS;

EID: 3042677708     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0591     Document Type: Article

References (20)

1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
2. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001;19: 1501-18.
3. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182-94.
4. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012-20.
5. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Investig 1998; 101:847-54.
6. Mathijssen RH, Verweij J, de Jonge MJ, et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002;20:81-7.
7. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol 2002;20:7-8.
8. de Jonge MJ, Sparreboom A, Planting AS, et al. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol 2000;18:187-94.
9. Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9:3246-53.
10. Sparreboom A, de Bruijn P, de Jonge MJ, et al. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl 1998;712:225-35.
11. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002;20:3293-301.
12. Gurney HP, Ackland S, Gebski V, Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998;16: 2299-304.
13. Miller AA, Rosner GL, Egorin MJ, et al. Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/ pharmacodynamics in women with solid tumors (CALGB 9763). Proc Am Soc Clin Oncol 2003;22:125.
14. Egorin MJ. Overview of recent topics in clinical pharmacology of anticancer agents. Cancer Chemother Pharmacol 1998;42:S22-30.
15. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002;86:1297-302.
16. Taxis K, Barber N. Ethnographic study of incidence and severity of intravenous drug errors. Br Med J 2003;326:684-7.
17. Anderson BJ, Ellis JF. Common errors of drug administration in infants: causes and avoidance. Paediatr Drugs 1999;1:93-107.
18. Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002;20:4303-12.
19. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7.
20. Innocenti Fr, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronsyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.